George P Patrinos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2643419/publications.pdf

Version: 2024-02-01

203 papers	7,263 citations	87888 38 h-index	71685 76 g-index
209 all docs	209 docs citations	209 times ranked	8618 citing authors

#	Article	IF	Citations
1	Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide. Human Genetics, 2022, 141, 1137-1157.	3.8	6
2	Horizon Scanning: Teaching Genomics and Personalized Medicine in the Digital Age. OMICS A Journal of Integrative Biology, 2022, 26, 101-105.	2.0	0
3	Identification and functional validation of novel pharmacogenomic variants using a next-generation sequencing-based approach for clinical pharmacogenomics. Pharmacological Research, 2022, 176, 106087.	7.1	9
4	Examining key factors impact on health science studentsâ€™ intentions to adopt genetic and pharmacogenomics testing: a comparative path analysis in two different healthcare settings. Human Genomics, 2022, 16, 9.	2.9	5
5	A formalization of one of the main claims of â€œCost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary interventionâ€•by Fragoulakis et al. 20191. Data Science, 2022, 5, 29-33.	0.9	0
6	Beyond the Microbiome: Germ-ganism? An Integrative Idea for Microbial Existence, Organization, Growth, Pathogenicity, and Therapeutics. OMICS A Journal of Integrative Biology, 2022, , .	2.0	0
7	The Role of Oral Antivirals for COVID-19 Treatment in Shaping the Pandemic Landscape. Journal of Personalized Medicine, 2022, 12, 439.	2.5	6
8	Development of an optimized and generic cost-utility model for analyzing genome-guided treatment data. Pharmacological Research, 2022, 178, 106187.	7.1	2
9	Pharmacogenomics: the low-hanging fruit in the personalized medicine tree. Human Genetics, 2022, , .	3.8	1
10	Discovery of new drug indications for COVID-19: A drug repurposing approach. PLoS ONE, 2022, 17, e0267095.	2.5	6
11	miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders. Pharmacogenomics Journal, 2022, 22, 211-222.	2.0	12
12	The Festival of Genetics and Personalized Medicine. Pharmacogenomics, 2022, 23, 509-511.	1.3	0
13	Clinically relevant updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Research, 2021, 49, D1192-D1196.	14.5	62
14	What Do Students in Pharmacy and Medicine Think About Pharmacogenomics and Personalized Medicine Education? Awareness, Attitudes, and Perceptions in Malaysian Health Sciences. OMICS A Journal of Integrative Biology, 2021, 25, 52-59.	2.0	11
15	Prevalence of pharmacogenomic variants in 100 pharmacogenes among Southeast Asian populations under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm). Human Genome Variation, 2021, 8, 7.	0.7	19
16	Pixel-Based Machine Learning and Image Reconstitution for Dot-ELISA Pathogen Diagnosis in Biological Samples. Frontiers in Microbiology, 2021, 12, 562199.	3.5	2
17	Stakeholdersâ€™ Interest and Attitudes toward Genomic Medicine and Pharmacogenomics Implementation in the United Arab Emirates: A Qualitative Study. Public Health Genomics, 2021, 24, 99-109.	1.0	8
18	Attitudes and Awareness Toward Pharmacogenomics and Personalized Medicine Adoption Among Health Sciences Trainees: Experience from Greece and Lessons for Europe. OMICS A Journal of Integrative Biology, 2021, 25, 190-199.	2.0	7

#	Article	IF	Citations
19	Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model. Pharmacogenomics Journal, 2021, 21, 476-483.	2.0	9
20	Exploiting the Role of Hypoxia-Inducible Factor 1 and Pseudohypoxia in the Myelodysplastic Syndrome Pathophysiology. International Journal of Molecular Sciences, 2021, 22, 4099.	4.1	3
21	Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics, 2021, 53, 817-829.	21.4	629
22	Mapping the Educational Environment of Genomics and Pharmacogenomics in the United Arab Emirates: A Mixed-Methods Triangulated Design. OMICS A Journal of Integrative Biology, 2021, 25, 285-293.	2.0	2
23	Discrepancies and similarities in the genome-informed guidance for psychiatric disorders amongst different regulatory bodies and research consortia using next generation sequencing-based clinical pharmacogenomics data. Pharmacological Research, 2021, 167, 105538.	7.1	5
24	Inaugural Pharmacogenomics Access and Reimbursement Symposium. Pharmacogenomics, 2021, 22, 515-517.	1.3	0
25	Genome-based therapeutic interventions for Î²-type hemoglobinopathies. Human Genomics, 2021, 15, 32.	2.9	10
26	Conference report: inaugural Pharmacogenomics Access & Reimbursement Symposium. Pharmacogenomics Journal, 2021, 21, 622-624.	2.0	0
27	Ethics and equity in rare disease research and healthcare. Personalized Medicine, 2021, 18, 407-416.	1.5	0
28	Economic evaluation in psychiatric pharmacogenomics: a systematic review. Pharmacogenomics Journal, 2021, 21, 533-541.	2.0	28
29	Fast, Scalable, and Practical: An Alkaline DNA Extraction Pipeline for Emergency Microbiomics Biosurveillance. OMICS A Journal of Integrative Biology, 2021, 25, 484-494.	2.0	4
30	A novel machine learning-based approach for the computational functional assessment of pharmacogenomic variants. Human Genomics, 2021, 15, 51.	2.9	14
31	Pharmacogenomics variants are associated with BMI differences between individuals with bipolar and other psychiatric disorders. Pharmacogenomics, 2021, 22, 749-760.	1.3	0
32	Adoption of Pharmacogenomic Testing: A Marketing Perspective. Frontiers in Pharmacology, 2021, 12, 724311.	3.5	8
33	A novel variant in DYNC1H1 could contribute to human amyotrophic lateral sclerosis-frontotemporal dementia spectrum.. Journal of Physical Education and Sports Management, 2021, , mcs.a006096.	1.2	8
34	Strategies to improve pharmacogenomic-guided treatment options for patients with Î²-hemoglobinopathies. Expert Review of Hematology, 2021, 14, 1-3.	2.2	0
35	The ethnogeographic variability of genetic factors underlying G6PD deficiency. Pharmacological Research, 2021, 173, 105904.	7.1	14
36	Catalyzing clinical implementation of pharmacogenomics and personalized medicine interventions in Africa. Pharmacogenomics, 2021, 22, 115-122.	1.3	2

#	Article	IF	Citations
37	Welcome to the 18th volume of Personalized Medicine. Personalized Medicine, 2021, 18, 1-3.	1.5	0
38	Development of the pharmacogenomics and genomics literacy framework for pharmacists. Human Genomics, 2021, 15, 62.	2.9	11
39	The importance of adherence to international standards for depositing open data in public repositories. BMC Research Notes, 2021, 14, 405.	1.4	12
40	Sketching the prevalence of pharmacogenomic biomarkers among populations for clinical pharmacogenomics. European Journal of Human Genetics, 2020, 28, 1-3.	2.8	2
41	Precision Medicine in Lowâ€•and Middleâ€Income Countries. Clinical Pharmacology and Therapeutics, 2020, 107, 29-32.	4.7	11
42	Legal Aspects of Genomic and Personalized Medicine. , 2020, , 259-274.		3
43	Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. Pharmacological Research, 2020, 153, 104590.	7.1	31
44	Genomics and Pharmacogenomics Knowledge, Attitude and Practice of Pharmacists Working in United Arab Emirates: Findings from Focus Group Discussionsâ€"A Qualitative Study. Journal of Personalized Medicine, 2020, 10, 134.	2.5	17
45	Roadmap for Establishing Large-Scale Genomic Medicine Initiatives in Low- and Middle-Income Countries. American Journal of Human Genetics, 2020, 107, 589-595.	6.2	11
46	Development of Rapid Pharmacogenomic Testing Assay in a Mobile Molecular Biology Laboratory (2MoBiL). OMICS A Journal of Integrative Biology, 2020, 24, 660-666.	2.0	3
47	Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. Human Genomics, 2020, 14, 40.	2.9	121
48	Knowledge, Attitudes, and Perceived Barriers toward Genetic Testing and Pharmacogenomics among Healthcare Workers in the United Arab Emirates: A Cross-Sectional Study. Journal of Personalized Medicine, 2020, 10, 216.	2.5	17
49	Evaluating the current level of pharmacistsâ€™Âpharmacogenomics knowledge and its impact on pharmacogenomics implementation. Pharmacogenomics, 2020, 21, 1179-1189.	1.3	10
50	A Novel Text-Mining Approach for Retrieving Pharmacogenomics Associations From the Literature. Frontiers in Pharmacology, 2020, 11, 602030.	3.5	5
51	Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts. Cancers, 2020, 12, 3520.	3.7	9
52	PARC report: health outcomes and value of personalized medicine interventions: impact on patient care. Pharmacogenomics, 2020, 21, 797-807.	1.3	14
53	Point-of-need molecular processing of biosamples using portable instrumentation to reduce turnaround time. Biosafety and Health, 2020, 2, 177-182.	2.7	13
54	LRF/ZBTB7A conservation accentuates its potential as a therapeutic target for the hematopoietic disorders. Gene, 2020, 760, 145020.	2.2	2

#	Article	IF	Citations
55	The Pharmacogenomics Journal: there is a new chief in town. Pharmacogenomics Journal, 2020, 20, 747-748.	2.0	0
56	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. Pharmacogenetics and Genomics, 2020, 30, 131-144.	1.5	26
57	Editorial: Pharmacogenetics Research and Clinical Applications: An International Landscape of the Accomplishments, Challenges, and Opportunities. Frontiers in Pharmacology, 2020, 11, 1217.	3.5	5
58	CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients. Frontiers in Pharmacology, 2020, 11, 1218.	3.5	11
59	Costing Methods as a Means to Measure the Costs of Pharmacogenomics Testing. journal of applied laboratory medicine, The, 2020, 5, 1005-1016.	1.3	5
60	Variation in 100 relevant pharmacogenes among emiratis with insights from understudied populations. Scientific Reports, 2020, 10, 21310.	3.3	14
61	Knowledge and Attitudes of Medical and Health Science Students in the United Arab Emirates toward Genomic Medicine and Pharmacogenomics: A Cross-Sectional Study. Journal of Personalized Medicine, 2020, 10, 191.	2.5	16
62	Nutrigenetics and nutrigenomics: ready for clinical use or still a way to go?. Personalized Medicine, 2020, 17, 171-173.	1.5	5
63	Towards harmonizing guidance for genome-informed drug treatment interventions: The show must go on. Pharmacological Research, 2020, 158, 104839.	7.1	2
64	Toward High-Throughput Fungal Electroculturomics and New Omics Methodologies in 21st-Century Microbiology and Ecology. OMICS A Journal of Integrative Biology, 2020, 24, 493-504.	2.0	5
65	Multiomics Analysis Coupled with Text Mining Identify Novel Biomarker Candidates for Recurrent Cardiovascular Events. OMICS A Journal of Integrative Biology, 2020, 24, 205-215.	2.0	3
66	Bacteriome and Archaeome: The Core Family Under the Microbiomic Roof. , 2020, , 7-27.		2
67	Delineating significant genome-wide associations of variants with antipsychotic and antidepressant treatment response: implications for clinical pharmacogenomics. Human Genomics, 2020, 14, 4.	2.9	7
68	Documentation of clinically relevant genomic biomarker allele frequencies in the nextâ€generation FINDbase worldwide database. Human Mutation, 2020, 41, 1112-1122.	2.5	7
69	Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy. Frontiers in Pharmacology, 2020, 11, 445.	3.5	30
70	Exome-Wide Analysis of the DiscovEHR Cohort Reveals Novel Candidate Pharmacogenomic Variants for Clinical Pharmacogenomics. Genes, 2020, 11, 561.	2.4	5
71	Screening for the C9ORF72 Expansion in Greek Huntington Disease Phenocopies and Controls and Meta-analysis of Current Data. Tremor and Other Hyperkinetic Movements, 2020, 10, 5.	2.0	5
72	The Metabolomic Status of the Differentiating Myeloid Lineage in MDS with Low and High Bone Marrow Blast Counts. Blood, 2020, 136, 32-33.	1.4	1

#	Article	IF	Citations
73	Continuous pharmacogenomics and genomic medicine education for healthcare professionals through electronic educational courses. Personalized Medicine, 2019, 16, 189-193.	1.5	6
74	Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions. Frontiers in Pharmacology, 2019, 10, 830.	3.5	26
75	Pharmacomicrobiomics informs clinical pharmacogenomics. Pharmacogenomics, 2019, 20, 731-739.	1.3	7
76	Rethinking Drug Repositioning and Development with Artificial Intelligence, Machine Learning, and Omics. OMICS A Journal of Integrative Biology, 2019, 23, 539-548.	2.0	67
77	Genomic variants in members of the KrÃ¼ppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in Î²-hemoglobinopathies patients. Pharmacogenomics, 2019, 20, 791-801.	1.3	3
78	VKORC1 variants as significant predictors of warfarin dose in Emiratis . Pharmacogenomics and Personalized Medicine, 2019, Volume 12, 47-57.	0.7	6
79	Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity. American Journal of Human Genetics, 2019, 104, 1158-1168.	6.2	43
80	Educating healthcare providers in the delivery of genomic medicine. Personalized Medicine, 2019, 16, 187-188.	1.5	4
81	Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow. Frontiers in Pharmacology, 2019, 10, 384.	3.5	44
82	A Noninvasive Ocular (Tear) Sampling Method for Genetic Ascertainment of Transgenic Mice and Research Ethics Innovation. OMICS A Journal of Integrative Biology, 2019, 23, 312-317.	2.0	3
83	The role of C9orf72 in neurodegenerative disorders: a systematic review, an updated meta-analysis, and the creation of an online database. Neurobiology of Aging, 2019, 84, 238.e25-238.e34.	3.1	27
84	Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in Î²-Thalassemia Intermedia: A Validation Cohort Study. Hemoglobin, 2019, 43, 27-33.	0.8	7
85	Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: It takes two to tango. American Journal of Hematology, 2019, 94, 737-740.	4.1	17
86	VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 5791.	4.1	16
87	The multi-faceted functioning portrait of LRF/ZBTB7A. Human Genomics, 2019, 13, 66.	2.9	34
88	New molecular diagnostic trends and biomarkers for amyotrophic lateral sclerosis. Human Mutation, 2019, 40, 361-373.	2.5	15
89	Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention. Pharmacogenomics Journal, 2019, 19, 438-445.	2.0	18
90	Drug-Induced Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis Call for Optimum Patient Stratification and Theranostics via Pharmacogenomics. Annual Review of Genomics and Human Genetics, 2018, 19, 329-353.	6.2	29

#	Article	IF	Citations
91	The New Age of -omics in Urothelial Cancer â€“ Re-wording Its Diagnosis and Treatment. EBioMedicine, 2018, 28, 43-50.	6.1	12
92	Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis. OMICS A Journal of Integrative Biology, 2018, 22, 52-64.	2.0	31
93	Rebooting Bioresilience: A Multi-OMICS Approach to Tackle Global Catastrophic Biological Risks and Next-Generation Biothreats. OMICS A Journal of Integrative Biology, 2018, 22, 35-51.	2.0	25
94	Culturomics: A New Kid on the Block of OMICS to Enable Personalized Medicine. OMICS A Journal of Integrative Biology, 2018, 22, 108-118.	2.0	36
95	Population pharmacogenomics: impact on public health and drug development. Pharmacogenomics, 2018, 19, 3-6.	1.3	6
96	Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine. Public Health Genomics, 2018, 21, 217-227.	1.0	11
97	Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea. Human Genomics, 2018, 12, 45.	2.9	10
98	Searching for Clinically Relevant Biomarkers in Geriatric Oncology. BioMed Research International, 2018, 2018, 1-7.	1.9	3
99	Humanome Versus Microbiome: Games of Dominance and Pan-Biosurveillance in the Omics Universe. OMICS A Journal of Integrative Biology, 2018, 22, 528-538.	2.0	20
100	Genetic Variations Associated with Sleep Disorders in Patients with Schizophrenia: A Systematic Review. Medicines (Basel, Switzerland), 2018, 5, 27.	1.4	12
101	Autophagy in Myelodysplastic Syndromes: The Role of HIF-1a/REDD1 Molecular Pathway. Blood, 2018, 132, 1808-1808.	1.4	4
102	An Exploratory Study of Radiation Dermatitis in Breast Cancer Patients. Anticancer Research, 2018, 38, 1615-1622.	1.1	4
103	Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations. Pharmacogenomics, 2017, 18, 687-699.	1.3	13
104	Key Pharmacogenomic Considerations for Sickle Cell Disease Patients. OMICS A Journal of Integrative Biology, 2017, 21, 314-322.	2.0	6
105	Pharmacogenetics of lithium effects on glomerular function in bipolar disorder patients under chronic lithium treatment: a pilot study. Neuroscience Letters, 2017, 638, 1-4.	2.1	13
106	Expanded national database collection and data coverage in the FINDbase worldwide database for clinically relevant genomic variation allele frequencies. Nucleic Acids Research, 2017, 45, D846-D853.	14.5	18
107	David Bowie and the Art of Slow Innovation: A Fast-Second Winner Strategy for Biotechnology and Precision Medicine Global Development. OMICS A Journal of Integrative Biology, 2017, 21, 633-637.	2.0	12
108	Allele Drop Out Conferred by a Frequent CYP2D6 Genetic Variation For Commonly Used CYP2D6*3 Genotyping Assays. Cellular Physiology and Biochemistry, 2017, 43, 2297-2309.	1.6	14

#	Article	IF	Citations
109	â€œMaking Sense of Genesâ€•by Kostas Kampourakis (Cambridge: Cambridge University Press, 2017). OMICS A Journal of Integrative Biology, 2017, 21, 687-688.	2.0	0
110	Sensitive Monogenic Noninvasive Prenatal Diagnosis by Targeted Haplotyping. American Journal of Human Genetics, 2017, 101, 326-339.	6.2	76
111	Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation. OMICS A Journal of Integrative Biology, 2017, 21, 429-439.	2.0	15
112	When more really means more: WGS standards and quality control. Human Mutation, 2017, 38, 903-903.	2.5	1
113	Advancing Global Precision Medicine: An Overview of Genomic Testing and Counseling Services in Malaysia. OMICS A Journal of Integrative Biology, 2017, 21, 733-740.	2.0	10
114	Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New â€œFast-Second Winnerâ€•Strategy. OMICS A Journal of Integrative Biology, 2017, 21, 647-657.	2.0	29
115	The Israeli National Genetic database: a 10-year experience. Human Genomics, 2017, 11, 5.	2.9	18
116	Medical education in pharmacogenomicsâ€”results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx). European Journal of Clinical Pharmacology, 2017, 73, 1247-1252.	1.9	73
117	Genomic variants in the FTO gene are associated with sporadic amyotrophic lateral sclerosis in Greek patients. Human Genomics, 2017, 11, 30.	2.9	21
118	Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in Î²-type hemoglobinopathy patients. Human Genomics, 2017, 11, 24.	2.9	11
119	Ten simple rules for international short-term research stays. PLoS Computational Biology, 2017, 13, e1005832.	3.2	3
120	Exploring public genomics data for population pharmacogenomics. PLoS ONE, 2017, 12, e0182138.	2.5	35
121	A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS ONE, 2016, 11, e0162866.	2.5	96
122	Pharmacometabolomics Informs Viromics toward Precision Medicine. Frontiers in Pharmacology, 2016, 7, 411.	3.5	14
123	Novel genetic risk variants for pediatric celiac disease. Human Genomics, 2016, 10, 34.	2.9	9
124	Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy. Public Health Genomics, 2016, 19, 352-363.	1.0	37
125	Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease. EBioMedicine, 2016, 5, 40-45.	6.1	25
126	Computational approaches in target identification and drug discovery. Computational and Structural Biotechnology Journal, 2016, 14, 177-184.	4.1	270

#	Article	IF	Citations
127	KrÃ¼ppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants. Blood, 2016, 127, 1856-1862.	1.4	124
128	Minimum information required for a DMET experiment reporting. Pharmacogenomics, 2016, 17, 1533-1545.	1.3	6
129	Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. Pharmacogenomics, 2016, 17, 1775-1784.	1.3	13
130	Correlation of SIN3A genomic variants with Î²-hemoglobinopathies disease severity and hydroxyurea treatment efficacy. Pharmacogenomics, 2016, 17, 1785-1793.	1.3	12
131	Pharmacogenomics education and research at the Department of Pharmacy, University of Patras, Greece. Pharmacogenomics, 2016, 17, 1865-1872.	1.3	9
132	Nutrigenomics 2.0: The Need for Ongoing and Independent Evaluation and Synthesis of Commercial Nutrigenomics Tests' Scientific Knowledge Base for Responsible Innovation. OMICS A Journal of Integrative Biology, 2016, 20, 65-68.	2.0	26
133	Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/Î²-thalassemia patients. Pharmacogenomics, 2016, 17, 393-403.	1.3	10
134	ePGA: A Web-Based Information System for Translational Pharmacogenomics. PLoS ONE, 2016, 11, e0162801.	2.5	14
135	HDAC3 role in medication consumption in medication overuse headache patients: a pilot study. Human Genomics, 2015, 9, 30.	2.9	7
136	The Implications of Metabotypes for Rationalizing Therapeutics in Infants and Children. Frontiers in Pediatrics, 2015, 3, 68.	1.9	4
137	Global implementation of genomic medicine: We are not alone. Science Translational Medicine, 2015, 7, 290ps13.	12.4	146
138	Cellular models to study bipolar disorder: A systematic review. Journal of Affective Disorders, 2015, 184, 36-50.	4.1	49
139	Success stories in genomic medicine from resource-limited countries. Human Genomics, 2015, 9, 11.	2.9	41
140	Enabling pharmacogenomic services: Informatics and computational discovery aspects. , 2015, , .		0
141	Introducing dAUTObase: a first step towards the global scale geoepidemiology of autoimmune syndromes and diseases. Bioinformatics, 2015, 31, 581-586.	4.1	6
142	Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. Pharmacogenomics, 2015, 16, 137-148.	1.3	47
143	Nutrigenomics: A controversy. Applied & Translational Genomics, 2015, 4, 50-53.	2.1	36
144	Whole genome sequencing in pharmacogenomics. Frontiers in Pharmacology, 2015, 06, 61.	3.5	40

#	Article	IF	Citations
145	A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemotherapy and Pharmacology, 2015, 75, 791-803.	2.3	46
146	TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner. Pharmacogenomics, 2015, 16, 1701-1712.	1.3	21
147	Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach. Human Genomics, 2015, 9, 12.	2.9	18
148	Identification of a novel homozygous SPG7 mutation by whole exome sequencing in a Greek family with a complicated form of hereditary spastic paraplegia. European Journal of Medical Genetics, 2015, 58, 573-577.	1.3	6
149	Meta-Analysis of Genes in Commercially Available Nutrigenomic Tests Denotes Lack of Association with Dietary Intake and Nutrient-Related Pathologies. OMICS A Journal of Integrative Biology, 2015, 19, 512-520.	2.0	35
150	Key challenges for nextâ€generation pharmacogenomics. EMBO Reports, 2014, 15, 472-476.	4.5	49
151	Public Health Pharmacogenomics. Public Health Genomics, 2014, 17, 245-247.	1.0	1
152	Critical appraisal of the views of healthcare professionals with respect to pharmacogenomics and personalized medicine in Greece. Personalized Medicine, 2014, 11, 15-26.	1.5	46
153	Economic Evaluation of Pharmacogenomics: A Value-Based Approach to Pragmatic Decision Making in the Face of Complexity. Public Health Genomics, 2014, 17, 256-264.	1.0	51
154	Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics, 2014, 15, 1223-1234.	1.3	90
155	Lithium-induced differential expression of SAT1 in suicide completers and controls is not correlated with polymorphisms in the promoter region of the gene. Psychiatry Research, 2014, 220, 1167-1168.	3.3	1
156	Assessment of the Pharmacogenomics Educational Environment in Southeast Europe. Public Health Genomics, 2014, 17, 272-279.	1.0	40
157	Developments in FINDbase worldwide database for clinically relevant genomic variation allele frequencies. Nucleic Acids Research, 2014, 42, D1020-D1026.	14.5	27
158	Stakeholder Analysis in Pharmacogenomics and Genomic Medicine in Greece. Public Health Genomics, 2014, 17, 280-286.	1.0	26
159	<i>Public Health Genomics</i> Joins Forces with the Genomic Medicine Alliance. Public Health Genomics, 2014, 17, 125-126.	1.0	3
160	A set of novel mining tools for efficient biological knowledge discovery. Artificial Intelligence Review, 2014, 42, 461-478.	15.7	2
161	Genetics and Societyâ€"Educating Scientifically Literate Citizens: Introduction to the Thematic Issue. Science and Education, 2014, 23, 251-258.	2.7	19
162	Bridging genomics research between developed and developing countries: the Genomic Medicine Alliance. Personalized Medicine, 2014, 11, 615-623.	1.5	22

#	Article	IF	Citations
163	Information technology meets pharmacogenomics: Design specifications of an integrated personalized pharmacogenomics information system. , 2014, , .		4
164	Individualizing fetal hemoglobin augmenting therapy for Î²-type hemoglobinopathies patients. Pharmacogenomics, 2014, 15, 1355-1364.	1.3	21
165	Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Research, 2014, 42, D1063-D1069.	14.5	361
166	RD-Connect: An Integrated Platform Connecting Databases, Registries, Biobanks and Clinical Bioinformatics for Rare Disease Research. Journal of General Internal Medicine, 2014, 29, 780-787.	2.6	159
167	Deciphering next-generation pharmacogenomics: an information technology perspective. Open Biology, 2014, 4, 140071.	3.6	41
168	Working towards personalization of Medicine: Genomics in 2014. Personalized Medicine, 2014, 11, 611-613.	1.5	4
169	Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nature Genetics, 2013, 45, 1160-1167.	21.4	513
170	Genetic tests obtainable through pharmacies: the good, the bad, and the ugly. Human Genomics, 2013, 7, 17.	2.9	44
171	Genomic variation in the MAP3K5 gene is associated with Î²-thalassemia disease severity and hydroxyurea treatment efficacy. Pharmacogenomics, 2013, 14, 469-483.	1.3	25
172	Genetics, genomics and society: the responsibilities of scientists for science communication and education. Personalized Medicine, 2012, 9, 633-643.	1.5	36
173	Ascertainment and critical assessment of the views of the general public and healthcare professionals on nutrigenomics in Greece. Personalized Medicine, 2012, 9, 201-210.	1.5	20
174	KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in Î²-hemoglobinopathy patients. Pharmacogenomics, 2012, 13, 1487-1500.	1.3	37
175	Microattribution and nanopublication as means to incentivize the placement of human genome variation data into the public domain. Human Mutation, 2012, 33, 1503-1512.	2.5	59
176	Human variome project country nodes: Documenting genetic information within a country. Human Mutation, 2012, 33, 1513-1519.	2.5	10
177	Response to 'Europe and direct-to-consumer genetic tests'. Nature Reviews Genetics, 2012, 13, 146-146.	16.3	4
178	Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase. Pharmacogenomics, 2011, 12, 49-58.	1.3	30
179	Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nature Genetics, 2011, 43, 295-301.	21.4	142
180	Recommendations for genetic variation data capture in developing countries to ensure a comprehensive worldwide data collection. Human Mutation, 2011, 32, 2-9.	2.5	25

#	Article	IF	Citations
181	A critical view of the general publicâ€™s awareness and physiciansâ€™ opinion of the trends and potential pitfalls of genetic testing in Greece. Personalized Medicine, 2011, 8, 551-561.	1.5	47
182	FINDbase: a worldwide database for genetic variation allele frequencies updated. Nucleic Acids Research, 2011, 39, D926-D932.	14.5	22
183	Locus-specific database domain and data content analysis: evolution and content maturation toward clinical usea. Human Mutation, 2010, 31, 1109-1116.	2.5	39
184	Triangulating in on Chimps, Neanderthals, and Man. Human Mutation, 2010, 31, V-V.	2.5	1
185	Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nature Genetics, 2010, 42, 801-805.	21.4	323
186	dAUTObase: Mining gems on autoimmune diseases utilizing web visualization technologies. , 2010, , .		4
187	Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics, 2010, 11, 1149-1167.	1.3	129
188	A New Scientific Journal Linked to a Genetic Database: Towards a Novel Publication Modality. Human Genomics and Proteomics, 2009, 1, .	1.5	11
189	Copy number variation and genomic alterations in health and disease. Genome Medicine, 2009, 1, 21.	8.2	4
190	Pharmacogenomics and Therapeutics of Hemoglobinopathies. Hemoglobin, 2008, 32, 229-236.	0.8	31
191	FINDbase: a relational database recording frequencies of genetic defects leading to inherited disorders worldwide. Nucleic Acids Research, 2007, 35, D690-D695.	14.5	52
192	HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update. Human Mutation, 2007, 28, 206-206.	2.5	175
193	National and ethnic mutation databases: recording populations' genography. Human Mutation, 2006, 27, 879-887.	2.5	41
194	DNA, diseases and databases: disastrously deficient. Trends in Genetics, 2005, 21, 333-338.	6.7	50
195	Hellenic National Mutation Database: a prototype database for mutations leading to inherited disorders in the Hellenic population. Human Mutation, 2005, 25, 327-333.	2.5	53
196	Molecular diagnosis of inherited disorders: lessons from hemoglobinopathies. Human Mutation, 2005, 26, 399-412.	2.5	68
197	Evidence for the molecular heterogeneity of sickle cell anemia chromosomes bearing the Î²S/Benin haplotype. American Journal of Hematology, 2005, 80, 79-80.	4.1	10
198	Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucleic Acids Research, 2004, 32, 537D-541.	14.5	285

#	Article	IF	Citations
199	Multiple interactions between regulatory regions are required to stabilize an active chromatin hub. Genes and Development, 2004, 18, 1495-1509.	5.9	157
200	Recording human globin gene variation. Hemoglobin, 2004, 28, v-vii.	0.8	13
201	HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. Human Mutation, 2002, 19, 225-233.	2.5	400
202	A new base substitution in the 5â€² regulatory region of the humanAÎ³ globin gene is linked with the Î²s gene. Human Genetics, 1996, 97, 357-358.	3.8	7
203	A new base substitution in the 5â€² regulatory region of the human A Î³ globin gene is linked with the Î² S gene. Human Genetics, 1996, 97, 357-358.	3.8	0